Role of ZEB1 in immune response, inflammation and membrane remodeling during neoplasia

Abstract

Immune response, inflammation, and lipid metabolism have important effects on cancer development and progression. Several proteins in tumoral cells and/or tumor microenvironment are involved in any of these processes, whereas some of them participate in all three, such as the zinc finger E-box-binding homeobox 1 (ZEB1) protein. This protein has been proposed to have an important role in invasion and metastasis of cancer cells, as well as to be involved in malignant transformation and resistance to cancer treatments. So, in this study, we present the participation of ZEB1 in immune, inflammatory, and membrane remodeling (lipid metabolism) processes, as well as its interaction with proteins that participate in them. Due to the importance of ZEB1 in cancer progression, it may be a potential biomarker of cancer prognosis and a target for the development of new cancer therapies.

Keywords

ZEB1 / cancer / immune response / inflammation / membrane / lipids / epithelial-mesenchymal transition / metastasis

References

[1] Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015; 35 Suppl: S185-98.

[2] Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140: 883-99.

[3] Khandia R, Munjal A. Interplay between inflammation and cancer. Adv Protein Chem Struct Biol. 2020; 119: 199-245.

[4] Kay J, Thadhani E, Samson L, Engelward B. Inflammation-induced DNA damage, mutations and cancer. DNA Repair (Amst). 2019; 83: 102673.

[5] Broadfield LA, Pane AA, Talebi A, Swinnen JV, Fendt S. Lipid metabolism in cancer: New perspectives and emerging mechanisms. Dev Cell. 2021; 56: 1363-93.

[6] Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020; 122: 4-22.

[7] Snaebjornsson MT, Janaki-Raman S, Schulze A. Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer. Cell Metab. 2020; 31: 62-76.

[8] Caramel J, Ligier M, Puisieux A. Pleiotropic Roles for ZEB1 in Cancer. Cancer Res. 2018; 78: 30-5.

[9] Sánchez-Tilló E, Siles L, de Barrios O, Cuatrecasas M, Vaquero EC, Castells A, et al. Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am J Cancer Res. 2011; 1: 897-912.

[10] Zhang Y, Xu L, Li A, Han X. The roles of ZEB1 in tumorigenic progression and epigenetic modifications. Biomed Pharmacother. 2019; 110: 400-8.

[11] Zhang P, Sun Y, Ma L. ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle. 2015; 14: 481-7.

[12] Perez-Oquendo M, Gibbons DL. Regulation of ZEB1 Function and Molecular Associations in Tumor Progression and Metastasis. Cancers (Basel). 2022; 14: 1864.

[13] Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019; 20: 69-84.

[14] Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15: 178-96.

[15] Debnath P, Huirem RS, Dutta P, Palchaudhuri S. Epithelial-mesenchymal transition and its transcription factors. Biosci Rep. 2022; 42: BSR20211754.

[16] Ashrafizadeh M, Ang HL, Moghadam ER, Mohammadi S, Zarrin V, Hushmandi K, et al. MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy. Biomolecules. 2020; 10: 1040.

[17] Fratini L, Jaeger M, de Farias CB, Brunetto AT, Brunetto AL, Shaw L, et al. Oncogenic functions of ZEB1 in pediatric solid cancers: interplays with microRNAs and long noncoding RNAs. Mol Cell Biochem. 2021; 476: 4107-16.

[18] Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008; 9: 582-9.

[19] Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009; 11: 1487-95.

[20] Katsura A, Tamura Y, Hokari S, Harada M, Morikawa M, Sakurai T, et al. ZEB1-regulated inflammatory phenotype in breast cancer cells. Mol Oncol. 2017; 11: 1241-62.

[21] Block CJ, Dyson G, Campeanu IJ, Watza D, Ratnam M, Wu G. A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer. Sci Rep. 2019; 9: 17807.

[22] Plaschka M, Benboubker V, Grimont M, Berthet J, Tonon L, Lopez J, et al. ZEB1 transcription factor promotes immune escape in melanoma. J Immunother Cancer. 2022; 10: e003484.

[23] Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012; 12: 298-306.

[24] Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn Y, Byers LA, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014; 5: 5241.

[25] Laviron M, Boissonnas A. Ontogeny of Tumor-Associated Macrophages. Front Immunol. 2019; 10: 1799.

[26] Cortés M, Sanchez-Moral L, de Barrios O, Fernández-Aceñero MJ, Martínez-Campanario MC, Esteve-Codina A, et al. Tumor-associated macrophages (TAMs) depend on ZEB1 for their cancer-promoting roles. EMBO J. 2017; 36: 3336-55.

[27] Li Y, Wang L, Pappan L, Galliher-Beckley A, Shi J. IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation. Mol Cancer. 2012; 11: 87.

[28] Dohadwala M, Wang G, Heinrich E, Luo J, Lau O, Shih H, et al. The role of ZEB1 in the inflammation-induced promotion of EMT in HNSCC. Otolaryngol Head Neck Surg. 2010; 142: 753-9.

[29] Gu K, Li MM, Shen J, Liu F, Cao JY, Jin S, et al. Interleukin-17-induced EMT promotes lung cancer cell migration and invasion via NF-κB/ZEB1 signal pathway. Am J Cancer Res. 2015; 5: 1169-79.

[30] Lalle G, Twardowski J, Grinberg-Bleyer Y. NF-κB in Cancer Immunity: Friend or Foe? Cells. 2021; 10: 355.

[31] van Hogerlinden M, Rozell BL, Toftgård R, Sundberg JP. Characterization of the progressive skin disease and inflammatory cell infiltrate in mice with inhibited NF-kappaB signaling. J Invest Dermatol. 2004; 123: 101-8.

[32] de Barrios O, Sanchez-Moral L, Cortés M, Ninfali C, Profitós-Pelejà N, Martínez-Campanario MC, et al. ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cells. Gut. 2019; 68: 2129-41.

[33] Huang R, Chen H, Liang J, Li Y, Yang J, Luo C, et al. Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy. J Cancer. 2021; 12: 5543-61.

[34] Mirzaei S, Saghari S, Bassiri F, Raesi R, Zarrabi A, Hushmandi K, et al. NF-κB as a regulator of cancer metastasis and therapy response: A focus on epithelial-mesenchymal transition. J Cell Physiol. 2022; 237: 2770-95.

[35] Jiang J, Wang K, Chen Y, Chen H, Nice EC, Huang C. Redox regulation in tumor cell epithelial-mesenchymal transition: molecular basis and therapeutic strategy. Signal Transduct Target Ther. 2017; 2: 17036.

[36] De Cock JM, Shibue T, Dongre A, Keckesova Z, Reinhardt F, Weinberg RA. Inflammation Triggers Zeb1-Dependent Escape from Tumor Latency. Cancer Res. 2016; 76: 6778-84.

[37] Płuciennik E, Nowakowska M, Pospiech K, Stępień A, Wołkowicz M, Gałdyszyńska M, et al. The role of WWOX tumor suppressor gene in the regulation of EMT process via regulation of CDH1-ZEB1-VIM expression in endometrial cancer. Int J Oncol. 2015; 46: 2639-48.

[38] Schwab A, Rao Z, Zhang J, Gollowitzer A, Siebenkäs K, Bindel N, et al. Zeb1 mediates EMT/plasticity-associated ferroptosis sensitivity in cancer cells by regulating lipogenic enzyme expression and phospholipid composition. Nat Cell Biol. 2024; 26: 1470-81.

[39] Chen X, Kang R, Kroemer G, Tang D. Ferroptosis in infection, inflammation, and immunity. J Exp Med. 2021; 218: e20210518.

[40] Liu C, Wang K, Liu W, Zhang J, Fan Y, Sun Y. ALOX15⁺ M2 macrophages contribute to epithelial remodeling in eosinophilic chronic rhinosinusitis with nasal polyps . J Allergy Clin Immunol. 2024; 154: 592-608.

[41] Yang J, Tian B, Brasier AR. Targeting Chromatin Remodeling in Inflammation and Fibrosis. Adv Protein Chem Struct Biol. 2017; 107: 1-36.

[42] Bernardes N, Fialho AM. Perturbing the Dynamics and Organization of Cell Membrane Components: A New Paradigm for Cancer-Targeted Therapies. Int J Mol Sci. 2018; 19: 3871.

[43] Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science. 1972; 175: 720-31.

[44] Mollinedo F, Gajate C. Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy: Thematic Review Series: Biology of Lipid Rafts. J Lipid Res. 2020; 61: 611-35.

[45] Vallejo AA, Fernández MS. FRET between non-substrate probes detects lateral lipid domain formation during phospholipase A2 interfacial catalysis. Arch Biochem Biophys. 2008; 480: 1-10.

[46] Morandi A, Taddei ML, Chiarugi P, Giannoni E. Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors. Front Oncol. 2017; 7: 40.

[47] Jiang L, Liu J, Shi Y, Tang B, He T, Liu J, et al. MTMR2 promotes invasion and metastasis of gastric cancer via inactivating IFNγ/STAT1 signaling. J Exp Clin Cancer Res. 2019; 38: 206.

[48] Cao F, Li DP, Wang L, Li M, Zhang H, Tao M. TRIM25 promotes oncogenic activities through regulation of ZEB1 in breast cancer. Int J Clin Exp Pathol. 2016; 9: 9751-60.

[49] Lindner P, Paul S, Eckstein M, Hampel C, Muenzner JK, Erlenbach-Wuensch K, et al. EMT transcription factor ZEB1 alters the epigenetic landscape of colorectal cancer cells. Cell Death Dis. 2020; 11: 147.

[50] Zhao M, DiPeri TP, Raso MG, Zheng X, Rizvi YQ, Evans KW, et al. Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. NPJ Breast Cancer. 2023; 9: 66.

[51] Wang Y, Xiong H, Liu D, Hill C, Ertay A, Li J, et al. Autophagy inhibition specifically promotes epithelial-mesenchymal transition and invasion in RAS-mutated cancer cells. Autophagy. 2019; 15: 886-99.

[52] Bertrand M, Petit V, Jain A, Amsellem R, Johansen T, Larue L, et al. SQSTM1/p62 regulates the expression of junctional proteins through epithelial-mesenchymal transition factors. Cell Cycle. 2015; 14: 364-74.

[53] Xu LZ, Li SS, Zhou W, Kang ZJ, Zhang QX, Kamran M, et al. p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA. Oncogene. 2017; 36: 304-17.

[54] Lin S, Chen Q, Tan C, Su M, Min L, Ling L, et al. ZEB family is a prognostic biomarker and correlates with anoikis and immune infiltration in kidney renal clear cell carcinoma. BMC Med Genomics. 2024; 17: 153.

[55] Zhang G, Tian X, Li Y, Wang Z, Li X, Zhu C. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1. Biomed Pharmacother. 2018; 97: 736-44.

[56] Ren J, Chen Y, Song H, Chen L, Wang R. Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. J Cell Biochem. 2013; 114: 1395-403.

[57] Fu D, Huang Y, Gao M. Hsa_circ_0057481 promotes laryngeal cancer proliferation and migration by modulating the miR-200c/ZEB1 axis. Int J Clin Exp Pathol. 2019; 12: 4066-76.

[58] Yin Y, Liu W, Shen Q, Zhang P, Wang L, Tao R, et al. The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. Mol Cancer Ther. 2019; 18: 1439-50.

[59] The UniProt Consortium. UniProt: the Universal Protein Knowledgebase in 2025. Nucleic Acids Res. 2025; 53: D609-17.

[60] GeneCards®: The Human Gene Database [Internet]. Weizmann Institute of Science; c1996- 2025 [cited 2024 Dec 16]. Available from: https://www.genecards.org/

[61] Benson DA, Cavanaugh M, Clark K, Karsch-Mizrachi I, Lipman DJ, Ostell J, et al. GenBank. Nucleic Acids Res. 2013; 41: D36-42.

[62] van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008; 65: 3756-88.

[63] Wong SHM, Fang CM, Chuah LH, Leong CO, Ngai SC. E-cadherin: Its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol. 2018; 121: 11-22.

[64] Shenoy S. CDH1 (E-Cadherin) Mutation and Gastric Cancer: Genetics, Molecular Mechanisms and Guidelines for Management. Cancer Manag Res. 2019; 11: 10477-86.

[65] Yu W, Yang L, Li T, Zhang Y. Cadherin Signaling in Cancer: Its Functions and Role as a Therapeutic Target. Front Oncol. 2019; 9: 989.

[66] Van den Bossche J, Laoui D, Naessens T, Smits HH, Hokke CH, Stijlemans B, et al. E-cadherin expression in macrophages dampens their inflammatory responsiveness in vitro, but does not modulate M2-regulated pathologies in vivo. Sci Rep. 2015; 5: 12599.

[67] Márquez MG, Favale NO, Leocata Nieto F, Pescio LG, Sterin-Speziale N. Changes in membrane lipid composition cause alterations in epithelial cell-cell adhesion structures in renal papillary collecting duct cells. Biochim Biophys Acta. 2012; 1818: 491-501.

[68] Kang S, Narazaki M, Metwally H, Kishimoto T. Historical overview of the interleukin-6 family cytokine. J Exp Med. 2020; 217: e20190347.

[69] Rose-John S. Interleukin-6 Family Cytokines. Cold Spring Harb Perspect Biol. 2018; 10: a028415.

[70] Tanaka T, Narazaki M, Kishimoto T. Interleukin (IL-6) Immunotherapy. Cold Spring Harb Perspect Biol. 2018; 10: a028456.

[71] Mitchell S, Vargas J, Hoffmann A. Signaling via the NFκB system. Wiley Interdiscip Rev Syst Biol Med. 2016; 8: 227-41.

[72] Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018; 18: 309-24.

[73] Jovičić EJ, Janež AP, Eichmann TO, Koren Š, Brglez V, Jordan PM, et al. Lipid droplets control mitogenic lipid mediator production in human cancer cells. Mol Metab. 2023; 76: 101791.

[74] Vegliante R, Di Leo L, Ciccarone F, Ciriolo MR. Hints on ATGL implications in cancer: beyond bioenergetic clues. Cell Death Dis. 2018; 9: 316.

[75] Youssef J, Badr M. Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol. 2011; 164: 68-82.

[76] Qian L, Zhu Y, Deng C, Liang Z, Chen J, Chen Y, et al. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases. Signal Transduct Target Ther. 2024; 9: 50.

[77] Christofides A, Konstantinidou E, Jani C, Boussiotis VA. The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. Metabolism. 2021; 114: 154338.

[78] Yoon M. The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions. Pharmacol Res. 2009; 60: 151-9.

[79] Luo X, Liao C, Quan J, Cheng C, Zhao X, Bode AM, et al. Posttranslational regulation of PGC-1α and its implication in cancer metabolism. Int J Cancer. 2019; 145: 1475-83.

[80] Dumauthioz N, Tschumi B, Wenes M, Marti B, Wang H, Franco F, et al. Enforced PGC-1α expression promotes CD8 T cell fitness, memory formation and antitumor immunity. Cell Mol Immunol. 2021; 18: 1761-71.

[81] Zhong X, Wu H, Ouyang C, Zhang W, Shi Y, Wang Y, et al. Ncoa2 Promotes CD8+ T cell-Mediated Antitumor Immunity by Stimulating T-cell Activation via Upregulation of PGC-1α Critical for Mitochondrial Function. Cancer Immunol Res. 2023; 11: 1414-31.

[82] Gerbec ZJ, Hashemi E, Nanbakhsh A, Holzhauer S, Yang C, Mei A, et al. Conditional Deletion of PGC-1α Results in Energetic and Functional Defects in NK Cells. iScience. 2020; 23: 101454.

[83] Mastropasqua F, Girolimetti G, Shoshan M. PGC1α: Friend or Foe in Cancer? Genes (Basel). 2018; 9: 48.

[84] Cheng CF, Ku HC, Lin H. PGC-1α as a Pivotal Factor in Lipid and Metabolic Regulation. Int J Mol Sci. 2018; 19: 3447.

[85] Inokuchi JI, Inamori KI, Kabayama K, Nagafuku M, Uemura S, Go S, et al. Biology of GM3 Ganglioside. Prog Mol Biol Transl Sci. 2018; 156: 151-95.

[86] Hakomori S, Handa K. GM3 and cancer. Glycoconj J. 2015; 32: 1-8.

[87] Inokuchi JI, Nagafuku M. Gangliosides in T cell development and function of mice. Glycoconj J. 2022; 39: 229-38.

[88] Huwiler A, Pfeilschifter J. Sphingolipid signaling in renal fibrosis. Matrix Biol. 2018; 68-69: 230-47.

[89] Strekalova T, Svirin E, Veniaminova E, Kopeikina E, Veremeyko T, Yung AWY, et al. ASD-like behaviors, a dysregulated inflammatory response and decreased expression of PLP1 characterize mice deficient for sialyltransferase ST3GAL5. Brain Behav Immun Health. 2021; 16: 100306.

[90] Mathow D, Chessa F, Rabionet M, Kaden S, Jennemann R, Sandhoff R, et al. Zeb1 affects epithelial cell adhesion by diverting glycosphingolipid metabolism. EMBO Rep. 2015; 16: 321-31.

[91] Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase——development of the energy sensor concept. J Physiol. 2006; 574: 7-15.

[92] Li W, Saud SM, Young MR, Chen G, Hua B. Targeting AMPK for cancer prevention and treatment. Oncotarget. 2015; 6: 7365-78.

[93] Wang N, Wang B, Maswikiti EP, Yu Y, Song K, Ma C, et al. AMPK-a key factor in crosstalk between tumor cell energy metabolism and immune microenvironment? Cell Death Discov. 2024; 10: 237.

[94] Wang X, Chen X, Zhou W, Men H, Bao T, Sun Y, et al. Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways . Acta Pharm Sin B. 2022; 12: 708-22.

[95] Wang B, Tontonoz P. Liver X receptors in lipid signalling and membrane homeostasis. Nat Rev Endocrinol. 2018; 14: 452-63.

[96] Astuti Y, Raymant M, Quaranta V, Clarke K, Abudula M, Smith O, et al. Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis. Nat Cancer. 2024; 5: 774-90.

[97] Schulman IG. Liver X receptors link lipid metabolism and inflammation. FEBS Lett. 2017; 591: 2978-91.

[98] Chen L, Zhao ZW, Zeng PH, Zhou YJ, Yin WJ. Molecular mechanisms for ABCA1-mediated cholesterol efflux. Cell Cycle. 2022; 21: 1121-39.

[99] Phillips MC. Is ABCA1 a lipid transfer protein? J Lipid Res. 2018; 59: 749-63.

[100] Wu K, Zou L, Lei X, Yang X. Roles of ABCA1 in cancer. Oncol Lett. 2022; 24: 349.

[101] Castella B, Kopecka J, Sciancalepore P, Mandili G, Foglietta M, Mitro N, et al. The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells. Nat Commun. 2017; 8: 15663.

[102] Belisario DC, Akman M, Godel M, Campani V, Patrizio MP, Scotti L, et al. ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma. Cells. 2020; 9: 647.

[103] Laplagne C, Ligat L, Foote J, Lopez F, Fournié JJ, Laurent C, et al. Self-activation of Vγ9Vδ2 T cells by exogenous phosphoantigens involves TCR and butyrophilins. Cell Mol Immunol. 2021; 18: 1861-70.

[104] Bochem AE, van der Valk FM, Tolani S, Stroes ES, Westerterp M, Tall AR. Increased Systemic and Plaque Inflammation in ABCA1 Mutation Carriers With Attenuation by Statins. Arterioscler Thromb Vasc Biol. 2015; 35: 1663-9.